ArticleResearch square2024
KRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation.
Konstantin Budyagan, Alexa C Cannon, Adam Chatoff, Nathaniel W Snyder, Alison M Kurimchak, James S Duncan, Jonathan Chernoff
Open access · greenAbstract readPreprint
In one paragraphArticle in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
7 authors at 3 institutions in 1 country.
Konstantin BudyaganDepartment of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.
Alexa C CannonDepartment of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.
Adam ChatoffDepartment of Cancer & Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, United States of America.
Nathaniel W SnyderDepartment of Cancer & Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0001-5643-8747 Alison M KurimchakCancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0003-2608-0128 James S DuncanCancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America.
Jonathan ChernoffCancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-4803-7836 Fox Chase Cancer Center · USTemple College · USDrexel University · US
Funding
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Dietmar J Kappes · 1985 to 2026
$138.8MTRAINING PROGRAM IN CANCER RESEARCHT32CA009035 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CHERNOFF, JONATHAN · 1985 to 2020
$10.5MMetabolic and epigenetic reprogramming in cyclin E high ovarian cancerR01CA259111 · NCI · WISTAR INSTITUTE · PI AIRD, KATHERINE MARIE, SNYDER, NATHANIEL W. · 2021 to 2025
$2.9MTargeting the Rac1 signaling pathway in malignant melanomaR01CA227184 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CHERNOFF, JONATHAN · 2018 to 2022
$2.5MTargeting the kinome in K-ras driven colorectal cancersR01CA211670 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI DUNCAN, JAMES STUART · 2017 to 2021
$2.1MQuantification of compartmentalized metabolism in eukaryotic systemsR01GM132261 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI SNYDER, NATHANIEL W. · 2019 to 2023
$1.8MNCI NIH HHS P30 CA006927NCI NIH HHS R01 CA211670NCI NIH HHS R01 CA227184NCI NIH HHS R01 CA259111NCI NIH HHS T32 CA009035NIGMS NIH HHS R01 GM132261
6 · The paper itselfAbstract
Identifiers
PMID38464238
PMCPMC10925460
OpenAlexW4392057513
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390